inducing several pro-invasive growth factors. In turn, these serve as extracellular targets of novel therapeutic strategies directed at both cancer-driving oncogenes and the modified tumor microenvironment.
Activating mutations in the tyrosine kinase domain of HER2 (ErbB2) have been identified in human cancers. Compared with wild-type HER2, mutant HER2 shows constitutively activate kinase activity and increased oncogenicity. Cells transformed by mutant HER2 are resistant to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors and exhibit an attenuated response to the HER2 antibody trastuzumab. We investigated herein pathways through which mutant HER2 alters the extracellular environment, potentially leading to drug resistance and the effect of simultaneously targeting HER2 and the tumor cell microenvironment with a therapeutic intent. Expression of mutant HER2 in mammary epithelial cells activated autocrine transforming growth factor (TGF) b1 signaling through a mechanism involving Rac1 and c-Jun N-terminal kinase-activating protein 1-dependent transcription. Cells transformed by an activating mutant of H-Ras (G12V) also expressed higher TGF-b1 level through Rac1 activation. In addition, mutant HER2 induced the EGFR ligands TGF-a and amphiregulin at the mRNA and protein levels. Vascular endothelial growth factor, a target of the TGF-b-Smad transcriptional regulation, was also induced as a result of expression of mutant HER2. Inhibition of TGF-b signaling with the Alk5 small molecule inhibitor LY2109761 reduced growth and invasiveness of cells expressing mutant HER2. Combined inhibition of intracellular and paracrine effects of mutant HER2 by trastuzumab and the EGFR antibody cetuximab were more efficient than single-agent therapies. These data suggest that mutations in oncogenes such as HER2 and Ras not only alter intracellular signaling but also influence on other components of the tumor microenvironment by
Introduction
The majority of cancer occurs as a result of alterations in oncogenes. Among these, gene mutation, amplification, or overexpression of HER2/Neu (ErbB2) and epidermal growth factor receptor (EGFR, ErbB1) have been found in various human cancers (Yarden and Sliwkowski, 2001; Sharma et al., 2007) . Ligands of EGFR bind to the ectodomain of the receptor, leading to the formation of catalytically active receptor homoand heterodimers in which the EGFR associates with other ErbB receptors. Although HER2 cannot bind any of the ErbB ligands directly, its catalytic activity can potently amplify signaling by ErbB-containing heterodimers (Pinkas-Kramarski et al., 1996; Graus-Porta et al., 1997; Wang et al., 1998; Worthylake et al., 1999; Yarden and Sliwkowski, 2001) . A number of studies have shown mutations in the kinase domain of EGFR and HER2 resulting in ligand-independent kinase activity and activation of cytoplasmic signal transducers that regulate proliferation, differentiation, motility, adhesion, protection from apoptosis, and transformation (Wang et al., 2006a; Sharma et al., 2007) .
Intragenic somatic mutations in the HER2 gene were reported in 5% of non-small-cell lung cancers, 5% of gastric carcinomas, 3% of colorectal carcinomas, and o5% of breast carcinomas (Stephens et al., 2004; Shigematsu et al., 2005; Lee et al., 2006) . These involve in-frame duplications/insertions in a small stretch within exon 20 that correspond to the identical nine-codon region in exon 20 of the EGFR gene, where duplications/ insertions have also been reported (Stephens et al., 2004; Shigematsu et al., 2005) . We have previously shown that mutant HER2 with an in-frame YVMA insertion at residue 776 (HER2 YVMA ), the most common abnormality detected in non-small-cell lung cancers specimens (Shigematsu et al., 2005) , results in a gain-of-function compared with wild-type HER2 (HER2 WT ) thus transforming normal epithelial cells and inducing tumors in vivo (Wang et al., 2006a) . HER2 YVMA is potently autophosphorylated and induces transphosphorylation of kinase-dead EGFR. Cells expressing HER2 YVMA are resistant to the EGFR tyrosine kinase inhibitors such as erlotinib and gefitinib, and exhibit an attenuated response to the HER2 inhibitors lapatinib and trastuzumab (Wang et al., 2006a) , suggesting that tumors with HER2 mutations may have a suboptimal response to these therapies when given single agents. In this study, we show that mutant HER2 significantly upregulates expression of multiple growth factors including transforming growth factor (TGF-b), TGF-a, amphiregulin, and vascular endothelial growth factor (VEGF). These ligands, on entering the surrounding extracellular matrix, initiate not only autocrine but also paracrine signaling that enhances the growth and survival of cocultured cells. Induction of TGF-b is also detected in cells expressing mutant H-Ras, and is dependent on the c-Jun N-terminal kinase (JNK)-activating protein 1 (AP1) pathway, which is activated in cells expressing mutant HER2 or H-Ras. These results suggest a mechanism through which gain-of-function oncogene mutations amplify their transforming potential by modifying the tumor microenvironment and, second, therapeutic strategies that simultaneously target both cancer-driving oncogenes and the tumor microenvironment.
Results
Autocrine TGF-b signaling is upregulated in cells expressing mutant HER2 MCF10A human mammary epithelial cells stably transfected by HER2 WT maintain an epithelial morphology. However, stable expression of HER2 YVMA induces a morphological change consistent with an epithelial-tomesenchymal transition (EMT), including disruption of E-cadherin localization at the cell junctions and expression of the mesenchymal N-cadherin ( Figure 1a ). As TGF-b is a potent inducer of EMT (Willis and Borok, 2007) , we examined the mRNA levels for all three isoforms of human TGF-bs. Quantitative RT-PCR indicated that both TGF-b1 and TGF-b3, but not TGF-b2, were markedly upregulated in cells expressing HER2 YVMA . An 8.3-fold and 3.8-fold increase were observed for TGF-b1 and TGF-b3, respectively, in MCF10A/HER2 YVMA cells compared with cells expressing the empty vector (MCF10A/vec), whereas the increase in both ligands was less than twofold in MCF10A/HER2 WT cells (Figure 1b ). These changes were also observed in BEAS2B human bronchial epithelial cells. The upregulation of TGF-b1 and TGF-b3 RNAs was abrogated by treating the HER2 YVMAexpressing cells with the HER2 tyrosine kinase inhibitor lapatinib (Rusnak et al., 2001) (Figure 1b ). Using the conditioned medium (CM) collected from MCF10A cells expressing HER2 WT , HER2 YVMA , or vector, we detected a 4-fold and 7.5-fold increase in TGF-b1 protein resulting from the expression of HER2 WT and HER2 YVMA , respectively, when compared with cells transfected with vector alone (Figure 1c ).
Phosphorylation of Smad2, which serves as an indicator of TGF-b signaling, was only detectable in MCF10A/HER2 YVMA cells but not in control or HER2 WT -expressing cells in the absence of added TGF-b (Figure 1d ), suggesting that autocrine TGF-b pathway is activated in the former. When cultured in Matrigel, MCF10A/HER2 YVMA cells, but not MCF10A/ HER2 WT cells, formed multiacinar structures that invaded the surrounding matrix. Inhibition of TGF-b signaling by LY2109761, a small molecule kinase inhibitor of type I and II TGF-b receptor kinases (Sawyer et al., 2004; Peng et al., 2005) , reduced the size, invasiveness, and cell number of colonies expressing mutant HER2 but had no effect on wild-type HER2expressing colonies (Figure 1e ).
Mutant HER2 induces TGF-b through activating Rac1 and JNK-AP1 pathway
Previous study has indicated that the AP1 mediates activation of the TGF-b1 promoter in both human and rat cells. Unlike this promoter, the human TGF-b2 promoter does not contain AP1-binding sites and is therefore under different transcriptional regulation (Kim et al., 1990; Malipiero et al., 1990; Weigert et al., 2000) . As the expression of HER2 YVMA induced TGF-b1 production but lacked an effect on TGF-b2 ( Figure 1b ), we speculated that HER2 YVMA may upregulate TGF-b1 transcription through activation of the JNK-AP1 pathway. Indeed, the level of phosphorylated (active) JNK was significantly elevated in MCF10A/HER2 YVMA cells compared with vector control or HER2 WT -expressing cells (Figure 2a ). Both lapatinib and a small molecule JNK inhibitor suppressed P-JNK as well as P-Smad2 in these cells, whereas the protein kinase C inhibitor bisindolylmaleimide II and TGF-b receptor kinase inhibitor (LY2109761) showed no effect on P-JNK (Figure 2a ). This suggests that JNK activation by HER2 YVMA is independent of protein kinase C and upstream of TGF-b signal transduction. It has been reported that p38 MAPK also upregulates TGF-b1 (Weigert et al., 2000) . However, MCF10A/HER2 YVMA exhibited a lower level of P-p38 compared with control cells arguing against p38 signaling as a mechanism for increased TGF-b1 expression. Both the JNK inhibitor and the AP1 inhibitor curcumin reduced TGF-b1 and TGF-b3 mRNA levels in MCF10A/HER2 YVMA cells (Figure 2b ) and the level of TGF-b1 in the CM (Figure 2c ), further supporting a role for the JNK-AP1 pathway in TGF-b overproduction in these cells.
A body of previous work has elucidated a signaling cascade to activate JNK during oncogenesis. This includes activation of several MAP3Ks, usually initiated by growth factors and mediated by the Rho-family GTPases, and the subsequent activation of MKK4/7, the kinase that activates JNK (reviewed in Heasley and Han, 2006) . Activity of the Rho-family GTPases was examined by glutathione S-transferase (GST)-Pak-binding domain (PBD) (for Rac1 and Cdc42) or GSTrhotekin (for RhoA) pulldown assay. Elevated Rac1 activity was observed in MCF10A/HER2 YVMA cells (Figure 2d ), whereas the Cdc42 and RhoA activities were comparable to those detected in control cells (data not shown). Expression of a dominant negative (DN)-Rac1 markedly decreased TGF-b1 and TGF-b3 mRNA levels in MCF10A/HER2 YVMA cells and the TGF-b1 level in the CM, whereas a constitutively active-Rac1 was sufficient to increase TGF-b1 transcript by 2.5-fold ( Figure 2e and immunofluorescence (right) images of MCF10A/HER2 WT and MCF10A/HER2 YVMA cells cultured to reach confluence. For immunofluorescence staining, cells growing on glass coverslips were fixed and stained using antibodies against E-cadherin (green) and N-cadherin (red). DAPI (blue), nuclear staining. Bar equals 50 mm. (b) MCF10A (left) or BEAS2B (right) cells stably expressing HER2 WT , HER2 YVMA , or empty vector were grown in complete medium and treated with lapatinib for 16 h or left untreated. Total RNA was extracted and subjected to reverse transcription followed by qPCR for TGF-b1, -b2, and -b3 as described in 'Materials and methods'. Data were normalized to the MCF10A/vec or BEAS2B/vec control cells. Each data represent mean±s.d. of three experiments. (c) Cells grown on 100-mm dishes (1 Â 10 6 cells/dish) were incubated for 24 h in serum-free medium. CM was collected and analyzed for total amount of TGF-b1 by ELISA as indicated in 'Materials and methods'. Data are normalized to pg/ml/10 6 cells/24 h. Each data represent mean±s.d. of three experiments. (d) Cells grown on six-well plates were serum-starved for 16 h before lysed. Cell lysates were subjected to immunoblot using indicated antibodies. (e) Top: MCF10A/HER2 WT and MCF10A/HER2 YVMA cells were plated in Matrigel in eightwell chambers and allowed to grow in the absence or presence of LY2109761 at the indicated concentrations. The inhibitor was added to the top medium 12 h after cell seeding and replenished every 3 days. Phase contrast images shown were recorded 9 days after the initial seeding of cells. Bottom: 9-day acini were trypsinized and total cell number was determined in a Coulter counter. Each bar graph represents mean±s.d. of four wells. autocrine TGF-b production and TGF-b-dependent EMT in cells transformed by this oncogene (Janda et al., 2002) . In keratinocytes containing mutant H-Ras, TGF-b1 production is enhanced whereas TGF-b2 is undetectable (Fahey et al., 1996) . Furthermore, both H-Ras and elevated levels of activated nuclear Smad2 are required for acquisition of EMT and metastatic progression in vivo (Oft et al., 2002) . To determine whether Rac1 and JNK-AP1-mediated transcription were also involved in TGF-b overproduction in cells transformed by mutant Ras, we stably expressed the active mutants of R-Ras (R-Ras G38V ) and H-Ras (H-Ras G12V ) in MCF10A cells. When cultured in Matrigel, H-Ras-transformed cells, but not R-Ras-or vector-expressing cells, formed multiacinar invasive structures, whose growth was inhibited by the Alk5 kinase inhibitor LY2109761 (Figure 3a ). H-Rastransformed cells contained higher levels of active Rac1, phosphorylated JNK, and phosphorylated Smad2 compared with cells expressing the vector alone or R-Ras. P-JNK and P-Smad2 were decreased by the expression of DN-Rac1 (Figure 3b ), suggesting that the Rac1-JNK-AP1 axis induces autocrine TGF-b in H-Ras-transformed cells. Furthermore, quantitative RT-PCR and ELISA indicated that H-Ras-transformed cells expressed significantly higher level of TGF-b1 than the other two lines and expression of DN-Rac1 or treatment with JNK or AP1 inhibitors markedly impaired TGF-b1 production (Figures 3c and d). (a) MCF10A/vec, MCF10A/HER2 WT , and MCF10A/HER2 YVMA cells were serum-starved for 16 h before treated with lapatinib (5 mM), JNK inhibitor (30 mM), LY2109761 (0.5 mM), or bisindolylmaleimide II (BIS II) (0.5 mM) for 4 h and lysed for immunoblot. (b) MCF10A/HER2 WT and MCF10A/ HER2 YVMA cells were grown in complete medium and treated with JNK inhibitor (30 mM) or AP1 inhibitor (5 mM) for 16 h or left untreated. Total RNA was extracted for RT-PCR. (c) Cells were treated as in (b) before incubated for 24 h in serum-free medium. CM was collected and analyzed for total amount of TGF-b1 by ELISA. (d) MCF10A/vec, MCF10A/HER2 WT , and MCF10A/HER2 YVMA cells grown on six-well plates were transiently transfected with a dominant negative (DN)-Rac1 construct or vector. At 40 h post transfection, cells were serum-starved for 8 h and lysed before incubation with GST-PBD. GST-PBD-bound proteins were eluted, separated by SDS-PAGE, and subjected to immunoblot using Rac1 antibody. Ponceau staining of the GST-PBD fusion was used as loading control. (e) MCF10A/HER2 WT and MCF10A/HER2 YVMA cells were transiently transfected with plasmid DNA encoding DN-Rac1, constitutively active (CA)-Rac1, or vector. At 48 h post transfection, total RNA was extracted for RT-PCR. (f) Cells were transfected as in (e) before incubated for 24 h in serum-free medium. CM was collected and analyzed for total amount of TGF-b1 by ELISA.
Mutant HER2 induces expression of EGFR ligands
We have shown earlier that cells expressing HER2 YVMA exihibit higher level of EGFR phosphorylation as a result of the constitutive association of EGFR and mutant HER2 and the transphosphorylation of EGFR by the latter (Wang et al., 2006a) . It is known that EGFR ligands auto-induce their expression and can also cross-induce other EGFR ligands. For example, TGF-a, amphiregulin, HB-EGF, and betacellulin can induce the mRNA expression of the remaining family members (Barnard et al., 1994) . Treatment with epiregulin induces the mRNA levels of TGF-a, amphiregulin, HB-EGF, and epiregulin within 1 h. In turn, EGF, TGF-a, amphiregulin, and HB-EGF can all induce epiregulin expression (Shirakata et al., 2000) . Therefore, we speculated that the ligand-independent activation of EGFR in cells expressing HER2 YVMA can also induce expression of multiple EGFR ligands. This was exam-ined in MCF10A and BEAS2B cells expressing HER2 WT , HER2 YVMA , or vector alone by quantitative RT-PCR using ligand-specific primers specific. In BEAS2B cells, expression of HER2 YVMA , but not HER2 WT , induced the mRNA levels of TGF-a, amphiregulin, and epiregulin by 2.7-6-fold ( Figure 4a ). Significant increase in mRNAs encoding TGF-a, amphiregulin, HB-EGF, and epiregulin was also observed in MCF10A cells expressing HER2 YVMA compared with cells expressing HER2 WT or vector alone ( Figure 4b ). In both cell lines, treatment with lapatinib inhibited the induction of EGFR ligands (Figures 4a  and b ). We next tested the levels of TGF-a and amphiregulin in the CM prepared from these cells using specific immunoassays. HER2 YVMA -expressing cells produced 4-to 7.5-fold higher levels of TGF-a ( Figure 4c ) and amphiregulin protein ( Figure 4d ) compared with the other two cell lines. EGFR ligands produced by cells expressing mutant HER2 stimulate paracrine signaling Cells expressing mutant HER2 exhibit ligand-independent constitutive EGFR and HER2 signaling. We speculated that their increased production of EGFR ligands will stimulate adjacent cells where activation of the EGFR is ligand dependent. This was first tested in the wild-type BEAS2B cells treated with serum-free CM collected from cells expressing HER2 YVMA or HER2 WT . CM of HER2 YVMA -expressing cells induced phosphorylation of EGFR and activation of the downstream effectors Akt and Erk in wild-type BEAS2B cells (Figure 5a ). These responses were inhibited by preincubating BEAS2B cells with the EGFR antibody cetuximab, which blocks ligand binding (Figure 5a ). As expected, cetuximab had no effect on the ligandindependent EGFR and HER2 signaling in cells expressing HER2 YVMA (Figure 5b) . We then used a coculture system in which wild-type target cells (either BEAS2B or MCF10A/HER2) growing in plates were co-incubated with but separated by a 0.4-mm pore-size filter from oncogene-expressing cells to determine the effect of CM from these cells on wild-type cell growth after 72 h. Co-incubation of BEAS2B or MCF10A/ HER2 cells with cells expressing HER2 YVMA , but not with cells expressing HER2 WT , or vector alone resulted in a significant increase in BEAS2B or MCF10A/HER2 target cell number (Figure 5c ). This increase in target cell number as a result of co-incubation with cells expressing mutant HER2 was abrogated by treatment with cetuximab (Figure 5c ), implying it was mediated by paracrine effects of EGFR ligands.
Mutant HER2 in H1781 cells is required for production of EGFR and TGF-b ligands
To validate our findings in cells naturally carrying HER2 mutation, we performed HER2 RNA interference in NCI-H1781 lung cancer cells, which contain a VC insertion at G776 in exon 20 of the HER2 gene (Shigematsu et al., 2005) . We and others have shown earlier that H1781 cells are homozygous and do not express wild type HER2 (Shigematsu et al., 2005; Wang et al., 2006a) . Small-interfering RNA oligonucleotides targeting HER2 WT , HER2 MUT , or a control sequence were transfected into H1781 cells as described (Wang et al., 2006a) . Three days post transfection, the mRNA levels of TGF-a, amphiregulin, betacellulin, and epiregulin were decreased by 50-60% only in cells transfected with siHER2(MUT) (Figure 6a ). Consistent with these results, levels of TGF-a and amphiregulin in the CM of transfected cells were also decreased by siHER2(MUT) but not siHER2(WT) (Figure 6b ). When the CM were used to treated BEAS2B cells, addition of medium collected from H1781 cells transfected with control siRNA or siHER2(WT) induced P-EGFR, P-Akt, and P-Erk in BEAS2B target cells; this was not observed with the CM from siHER2(MUT)-transfected H1781 cells (Figure 6c ). In addition, knock down of HER2 MUT by siRNA also decreased TGF-b1 mRNA levels (Figure 6d ) and protein levels in CM (Figure 6e ), suggesting that mutant HER2 is required for the production of EGFR ligands and TGF-b1 in H1781 cells.
Combined inhibition of intracellular and paracrine effects of mutant HER2
We have shown earlier that in 3D Matrigel supplemented with EGF, MCF10A/HER2 WT cells form roundshaped acinus-like structures with a hollow lumen, whereas MCF10A/HER2 YVMA cells form multiacinar structures with invading protrusions into the surrounding matrix (Wang et al., 2006a) (Figure 1e ). However, when no EGF was added into the top medium, MCF10A/HER2 WT cells showed highly restricted growth (Figure 7a ) thus providing a model to test the biological effect of EGFR ligands secreted by adjacent HER2 YVMA -expressing cells. The MCF10A/HER2 WT cells and MCF10A/HER2 YVMA cells were differentially labeled with fluorescent linkers and cultured on Matrigel in the absence of EGF either alone or in a 1:1 combination. On day 6, the MCF10A/HER2 YVMA cells grew into multiacinar structures in an EGF-independent manner, whereas the MCF10A/HER2 WT cells did not when cultured alone. However, the MCF10A/HER2 WT Figure 5 EGFR ligands produced by cells expressing mutant HER2 stimulate paracrine signaling. (a) CM was prepared by incubating BEAS2B/HER2 WT or BEAS2B/HER2 YVMA cells grown on 100-mm dishes (1 Â 10 6 cells/dish) in serum-free medium for 24 h followed by filtration of collected medium through a 0.22-mm sterile filter. Wild-type BEAS2B cells grown on six-well plates were serum-starved for 16 h before treated with different CM for 1 h. In the indicated lanes, cetuximab (10 mg/ml) was added to the target cells 2 h prior the addition of the CM. Cell lysates were subjected to immunoblot with indicated antibodies. (b) BEAS2B/HER2 WT or BEAS2B/ HER2 YVMA cells were serum-starved for 16 h and treated with cetuximab (10 mg/ml) for 16 h or left untreated. Cell lysates were subjected to immunoblot with indicated antibodies. (c) Co-culture assay was performed as described in 'Materials and methods' using transwell tissue-culture inserts. Co-cultures were carried out as indicated in serum-free medium in the presence or absence of cetuximab (10 mg/ml) for 72 h. Target cells were collected by trypsinization and cell number was determined in a Coulter counter. Each data represent mean±s.d. of three wells. Right: a schematic representation of the two-story co-culture experiments. cells regained the ability to grow into regular-sized acini when co-cultured with the MCF10A/HER2 YVMA cells (Figure 7a ). Treatment with trastuzumab modestly inhibited growth and invasiveness of HER2 YVMA but not EGF-stimulated HER2 WT acini in 3D co-culture (Figures 7b and c) . This lack of effect of trastuzumab on MCF10A/HER2 WT cells is consistent with the reported inability of the antibody to interfere with ErbB ligandinduced growth and/or EGFR/HER2 heterodimerization (Ye et al., 1999; Moulder et al., 2001; Agus et al., 2002) . In contrast, cetuximab completely inhibited growth of MCF10A/HER2 WT cells but had no effect on the ligand-independent growth of MCF10A/HER2-YVMA cells in the co-culture system (Figures 7b and c) . When the two antibodies were added to the co-culture, growth of both cell types was inhibited (Figures 7b and c) .
Mutant HER2 upregulates VEGF expression
VEGF is an important cancer-promoting angiogenic factor and thus a therapeutic target in the tumor microenvironment. Transcription of VEGF gene is upregulated by numerous transcription factors and signaling pathways, including the hypoxia-inducible factor-1a and TGF-b (Josko and Mazurek, 2004) . Hypoxia and TGF-b cooperate to induce VEGF gene expression through a region on the VEGF promoter, which contains functional DNA-binding sequences for hypoxia-inducible factor-1a and Smads (Sanchez-Elsner et al., 2001) . Therefore, we investigated whether activated autocrine TGF-b in cells expressing HER2-YVMA upregulates VEGF expression using quantitative RT-PCR. In both BEAS2B and MCF10A cells, expression of HER2 YVMA significantly increased VEGF transcription by 6-and 4.5-fold, respectively (Figure 8a) . This induction was inhibited by lapatinib, LY2109761, or transduction with a Smad7 adenovirus (Figure 8a) . Finally, we examined the effect of CM collected from BEAS2B cells expressing HER2 WT , HER2 YVMA , or vector on endothelial cell (EC) migration. CM from BEAS2B/ HER2 YVMA cells exhibited a higher potential to induce EC migration through the transwell filters than CM Figure 6 RNA interference of mutant HER2 inhibits growth factor production of H1781 lung cancer cells. (a, d) H1781 cells were transfected by siRNA oligonucleotides targeting HER2 WT , HER2 MUT , or a control sequence. At day 3 after transfection, total RNA was extracted and subjected to RT-PCR. Data were normalized to the H1781 cells transfected by control siRNA. Each data represent mean±s.d. of three experiments. (b, e) At day 3 after siRNA transfection, H1781 cells grown on 100-mm dishes (1 Â 10 6 cells/dish) were incubated for 24 h in serum-free medium. CM was collected and analyzed for total amount of TGF-a, amphiregulin (b), or TGF-b1 (e) by immunoassays. Data are normalized to pg/ml/10 6 cells/24 h. Each data represent mean ± s.d. of three experiments. (c) CM collected from H1781 cells transfected by siRNA was added to serum-starved BEAS2B cells. In the indicated lanes, cetuximab (10 mg/ ml) was added to the target cells 2 h prior the addition of the CM. BEAS2B cell lysates were prepared after treatment with CM for 1 h and subjected to immunoblot with indicated antibodies.
Oncogenic mutations induce multiple growth factors SE Wang et al from the other two lines (Figure 8b ). This paracrine effect required HER2, TGF-b receptor, and VEGF receptor kinase activities as lapatinib, LY2109761, and SU5416, a small molecule inhibitor of VEGFR tyrosine kinases, inhibited CM-stimulated EC migration (Figures 8b-d) .
Discussion
Solid tumors are heterogeneous tissues composed of tumor, stromal and immune cells, extracellular matrix, connective tissue, and blood vessels. In the tumor niche, cells harboring oncogenes such as HER2 and Ras mutations coexist with genetically wild-type host cells. As a result of these gain-of-function gene mutations, cells expressing oncogenes exhibit advantageous growth and survival over their wild-type countertypes, leading to clonal selection in the tumor microenvironment. Meanwhile, these oncogene-expressing cells may also influence adjacent wild-type cells by modifying this microenvironment. Herein, we showed that an activating mutant of HER2 upregulates expression of multiple growth factors including TGF-b, VEGF, and a variety of EGFR ligands including TGF-a and amphiregulin, both of which have shown special relevance to tumor growth among other EGFR ligands (Normanno et al., 2001) . These growth factors overproduced by the cells carrying oncogenes initiate not only autocrine but also paracrine signaling that favors tumor growth. Our data also suggest that the efficacy of current oncogenetargeted therapies may be potentiated by rationally cotargeting both the intracellular and the environmental effects of the oncogene. In the mixed culture of cells each Figure 7 Combined inhibition of intracellular and paracrine effects of mutant HER2. (a) MCF10A/HER2 WT cells were labeled with PKH67 green fluorescent cell linker amd MCF10A/HER2 YVMA cells were labeled with PKH26 red fluorescent cell linker. Labeled cells were immediately seeded in Matrigel for 3D culture in the absence of EGF in the top medium. Top: for single cell type culture, 6 Â 10 3 cells were seeded on day 0. Bottom: for co-culture of mixed cell types, 3 Â 10 3 cells of each cell type (a total of 6 Â 10 3 cells) were seeded on day 0. The fluorescent images were captured on day 6. Bars equal 100 mm. (b) Co-culture of differently labeled 10A/HER2 WT and 10A/HER2 YVMA cells was set up as described in (a). At 12 h after cell seeding, trastuzumab (10 mg/ml) and/or cetuximab (10 mg/ml) was added into the top medium as indicated. Antibodies were replenished every 3 days. The fluorescent images were photographed on day 6. (c) The 6-day acini in (a, b) were trypsinized and total cell number of each labeled cell type was determined. Each bar graph represents mean±s.d. of three wells.
expressing mutant HER2 and wild-type HER2, the HER2 and EGFR antibodies trastuzumab or cetuximab, respectively, inhibited only one cell population. Simultaneous treatment with both antibodies was required for inhibition of both cell populations (Figures  7b and c) . Among the growth factors induced by HER2 and Ras oncogenes, TGF-b ligands are known to foster cancer progression by mechanisms that include an increase in tumor neoangiogenesis and extracellular matrix production, upregulation of peri-tumor proteases, and inhibition of mechanisms of immune surveillance in the cancer host, among others (Dumont and Arteaga, 2003) . Many of the cancer-promoting functions of TGF-b are exerted through the cooperation between TGF-b and transforming oncogenes, such as ErbB2/HER2/Neu, polyomavirus middle T antigen (PyVmT), and Ras (Janda et al., 2002; Muraoka et al., 2003; Siegel et al., 2003; Muraoka-Cook et al., 2004; Seton-Rogers et al., 2004; Ueda et al., 2004) . Among the three TGF-b homologous forms in human, TGF-b1 is most frequently overexpressed in tumor cells (Derynck et al., 2001) . Interference of TGF-b signaling with a small molecule inhibitor of the type I receptor serine threonine kinase blocked invasiveness of tumor cells expressing mutant HER2 or mutant Ras (Figures 1e and 3a ), suggesting tumor cell autonomous mechanisms of dependence on TGF-b signaling in oncogene-transformed cells.
A link between EGFR, Ras, and TGF-b signaling has been established. For example, Ras-MEK downstream of EGFR signaling induces phosphorylation of TGIF, a Smad co-repressor that competes with the co-activator p300 for Smad2 association. This results in TGIF stabilization, formation of Smad2-TGIF co-repressor complexes, and abrogation of TGF-b-induced inhibition of cell proliferation mediated by Smad2 target genes (Lo et al., 2001) . Our study herein suggests that mutants of HER2 and H-Ras also upregulate autocrine TGF-b Figure 8 Mutant HER2 upregulates VEGF expression in TGF-b-dependent manner. (a) Cells were treated either with lapatinib or with LY2109761 or infected with an adenovirus encoding Smad7 or b-Gal (MOI 1:5) as described (Wang et al., 2005) 16 h before total RNA was extracted for RT-PCR using primers for VEGF. (b) CM was prepared from cells treated with lapatinib or from untreated cells as described in Figure 1c . After concentrated by 10-fold as described in 'Materials and methods', CM was added to EC in EC migration assay. Each data represent mean±s.d. of three experiments. (c) CM was prepared from cells treated with LY2109761 or from untreated cells, concentrated, and examined in EC migration assay. (d) CM from 2B/HER2 WT and 2B/HER2 YVMA cells were examined in EC migration assay as described in 'Materials and methods'. SU5416 (5 mM) was added to EC cells at the beginning of migration assay when indicated. *Po0.005. signaling by increasing the production of TGF-b ligands, such that other cells in the vicinity will be affected by cells carrying these mutations. This upregulation was mediated by the Rac1-JNK-AP1 axis, which is activated by HER2 and H-Ras. Notably, transient expression of CA-Rac1 was sufficient to induce 2.5-fold increase of TGF-b1 expression (Figure 2e ). This mechanism may also apply to cells harboring other oncogenes that activate Rac1 or JNK-AP1. Overexpression of Rac1 occurs in many tumor types including cancers of the breast, lung, and colon (Fritz et al., 1999; Schnelzer et al., 2000) . Both JNK and AP1 are known to be activated during tumor development and are potential therapeutic targets in cancer (Wagner and Nebreda, 2009 ). Our report suggests that elevated level/ activity of Rac1, JNK, or AP1 are causal to the high levels of TGF-b expression observed in many human cancers.
The Rac1 GTPase has been shown to contribute to TGF-b-mediated cellular and transcriptional responses (Mucsi et al., 1996; Atfi et al., 1997) . In addition, TGF-b can rapidly activate RhoA and Rac1, contributing to EMT and enhanced cell motility (Bhowmick et al., 2001; Bakin et al., 2002) . Rac1 activity in situ is higher in mouse mammary cancers expressing Neu (ErbB2) and active TGF-b1 transgenes compared with transgenic tumors expressing the Neu oncogene alone (Muraoka et al., 2003) . Rac1 is one of the immediately early targets of growth factors and oncogenes such as HER2 and Ras signaling (Adam et al., 1998; Bourguignon et al., 2001) . Therefore, these data suggest that oncogenic signaling that results in Rac1 activation contributes to high levels of TGF-b1 at tumor sites, which, in turn, facilitate the cooperation between TGF-b1 and oncogenes to promote cancer progression and further stimulate Rac1 activity in a positive feedback manner. Moreover, blockade of Rac1-induced TGF-b overproduction by JNK or AP1 inhibitors may serve as another strategy to target the high TGF-b levels in oncogene-driven tumors, in addition to the direct tumor cell autonomous effect of these inhibitors.
Mutant HER2 also upregulated VEGF expression and inhibition of the HER2 tyrosine kinase by lapatinib blocked this effect (Figure 8 ). Along those lines, inhibition of EGFR, Ras, or PI3K has been shown to decrease VEGF promoter activity and mRNA level in glioblastoma cell line through a mechanism distinct from signals induced by hypoxia (Maity et al., 2000) . Herein, we also showed that inhibition of TGF-b (by LY2109761) or Smad2/3 (by Smad7) also suppressed the induction of VEGF by mutant HER2. Considering that blockade of TGF-b signaling by LY2109761 inhibited the malignant phenotype of oncogene-transformed cells (Figures 1e and 3a) , the capacity of TGF-b-targeted therapy to inhibit both cancer cell growth and tumorinduced angiogenesis makes it a promising therapeutic strategy that aims at multiple compartments in the cancer niche. Future clinical investigation of TGF-b pathway inhibitors in combination with anti-oncogene therapies in selected types of cancers will shed light on this possibility.
Materials and methods
Cell lines and reagents BEAS2B human bronchial epithelial cells and MCF10A human mammary epithelial cells stably expressing wild-type HER2 (HER2 WT ), mutant HER2 with a G776 YVMA insertion in exon 20 (HER2 YVMA ), or vector alone, as well as NCI-H1781 lung cancer cells have been described elsewhere (Shigematsu et al., 2005; Wang et al., 2006a) . MCF10A cells stably expressing R-Ras G38V or H-Ras G12V were generated using LZRS-GFP retroviral vector encoding the Ras mutants (Erdogan et al., 2007) and selection for GFP positivity. Human ECs were cultured as described (DeBusk et al., 2004) (Fong et al., 1999) . Constructs encoding DN-Rac1(T17N) and constitutively active-Rac1(Q61L) are described elsewhere (Wang et al., 2006b) .
Immunoblot analysis and Rac1 activity assay
Immunoblot analyses were performed as described earlier (Wang et al., 2006a) . Primary antibodies included P-p38, p38, P-ERK1/2, ERK1/2, P-Akt S473 , Akt, P-EGFR Y1068 , P-HER2 Y1248 , P-JNK T183/Y185 , JNK (Cell Signaling, Danvers, MA, USA), Rac1 (BD Transduction Laboratories, San Jose, CA, USA), HER2, and EGFR (NeoMarkers, Fremont, CA, USA). To pull-down GTP-bound (active) Rac, a GST fusion protein of PBD pre-coupled to agarose-glutathione beads (Cytoskeleton Inc., Denver, CO, USA) was used as described earlier (Ueda et al., 2004) . Eluted Rac1 was detected by immunoblot.
Transfection of DNA and siRNA, RNA extraction, reverse transcription, and real-time quantitative qPCR analysis Cell transfection and the sequences of HER2 WT and HER2 MUT siRNA oligonucleotides were described earlier (Wang et al., 2006a) . RNA was isolated using the RNeasy Mini kit (Qiagen, Valencia, CA, USA) according to the manufacturer's procedures. After treatment with RQ1 RNase-free DNase (Promega, Madison, WI, USA), RNA samples were subjected to first-strand cDNA synthesis using Superscript II reverse transcriptase (Invitrogen, Carlsbad, CA, USA) following the manufacturer's protocols. Gene expression was quantified by qPCR using iQ SYBR green supermix (Bio-Rad, Hercules, CA, USA) and 50 ng of cDNA per reaction. The sequences of the primer sets used for this analysis are as follows: VEGF-A: F 5 0 -TTGCCTTGCTGCTCTACCTC-3 0 , R 5 0 -AAATGCTTTCTCCGCTCTGA-3 0 ; TGF-b1: F 5 0 -GCA CGTGGAGCTGTACCA-3 0 , R 5 0 -CAGCCGGTTGCTGAG GTA-3 0 ; TGF-b2: F 5 0 -CAAAGGGTACAATGCCAACTT-3 0 , R 5 0 -CAGATGCTTCTGGATTTATGGTATT-3 0 ; TGF-b3: F 5 0 -AAGAAGCGGGCTTTGGAC-3 0 , R 5 0 -CACACAGCA GTTCTCCTCCA-3 0 , where F and R are the forward and reverse primers, respectively. Primers for the ErbB ligands are described elsewhere (Wang et al., 2008) . Human cDNA FLJ22101 fis (GenBank accession number AK025754) was used as a housekeeping gene for normalization. Primer sets for FLJ22101 are as follows: F 5 0 -TTCCCTGTGGCACTTGACA TT-3 0 , R 5 0 -CTTTTGCCTCTGGCAGTACTCA-3 0 . An annealing temperature of 57 1C was used for all the primers. PCR reactions were performed in a standard 96-well plates format with Bio-Rad iQ 5 multicolor real-time PCR detection system. For data analysis, raw Ct was first normalized to the housekeeping gene for each sample to obtain dCt. The normalized dCt was then calibrated to control cell samples to obtain ddCt.
TGF-b1, TGF-a, and amphiregulin immunoassays Cells grown on 100-mm dishes (1 Â 10 6 cells/dish) were incubated for 24 h in serum-free medium. CM was collected, pre-cleared by centrifugation, and analyzed for total amount of TGF-b1, TGF-a, and amphiregulin using Quantikine human TGF-b1 or TGF-a immunoassay kit (R&D Systems, Minneapolis, MN, USA) and DuoSet human amphiregulin kit (R&D Systems), respectively. Plate preparation and assay procedures were performed according to the manufacturer's protocols. Each value was normalized by total protein concentration of each sample. For immunoassays of TGF-a and amphiregulin, cetuximab (10 mg/ml) was added at the beginning of the incubation to prevent ligand binding to the EGFR and their subsequent internalization.
Co-culture cell growth assays Co-culture assays were performed using transwell tissueculture inserts with a 0.4-mm microporous membrane (Becton Dickinson Labware, Franklin Lakes, NJ, USA). Target cells were plated (2 Â 10 4 ) onto the bottom of 12-well plates. Medium-conditioning cells (5 Â 10 3 ) were plated on the permeable membrane of tissue-culture inserts, which were then introduced into target cell-containing wells. Co-cultures were carried out in serum-free medium in the presence or absence of cetuximab (10 mg/ml). After 72 h, the test cells on the bottom of the wells were collected by trypsinization and cell number was determined in a Coulter counter. A schematic representation of the co-culture experiments is shown in Figure 5c .
3D morphogenesis and indirect immunofluorescence
Cells were seeded on growth factor reduced Matrigel (BD Biosciences, San Jose, CA, USA) in eight-well chamber slides following the protocol described by Debnath et al. (2003) . In the case of co-culture, cells were labeled with PKH67 green (for MCF10A/HER2 WT cells) or PKH26 red (for MCF10A/ HER2 YVMA cells) fluorescent cell linkers (Sigma) according to manufacturer's protocol. Labeled cells were immediately seeded on Matrigel following the protocol described by Debnath et al. (2003) except that EGF was omitted from the top medium. For single-cell cultures, 6 Â 10 3 cells were seeded on day 0, whereas for co-culture of mixed cell types, 3 Â 10 3 cells of each cell type (a total of 6 Â 10 3 cells) were seeded.
Inhibitors were added into the medium 12 h after cell seeding. The fluorescent images were captured on day 6 using Zeiss LSM510 confocal microscopy system. Acini were trypsinized and total cell number of each labeled cell type was determined under an upright fluorescent microscope. Indirect immunofluorescence assay was performed as described earlier (Wang et al., 2005) . Fluorescent images were captured using a Princeton Instruments cooled CCD digital camera from a Zeiss Axiophot upright microscope. Primary antibodies include E-cadherin and N-cadherin. The fluorescent antibodies are Oregon Green-a-mouse IgG and Texas Red-a-rabbit IgG (Molecular Probes, Carlsbad, CA, USA).
EC migration assay
Polyvinylpyrrolidone-free polycarbonate transwells with 8-mm pores (Costar, Lowell, MA, USA) were pre-coated with a mixture of collagen I (20 mg/ml) and collagen IV (10 mg/ml) overnight at 4 1C. After blocking the filters with 3% BSA in PBS to inhibit nonspecific migration, the lower wells of the chamber were filled with 0.4 ml of concentrated CM collected from BEAS2B/vec, BEAS2B/HER2 WT , or BEAS2B/HER2 YVMA cells. Added CM had been concentrated 10-fold using 5K Centrifugal Filters (Amicon, Billerica, MA, USA). Human ECs were collected from subconfluent cultures and resuspended in the same concentrated CM. A total of 5 Â 10 4 cells/100 ml were added to the upper chamber and then incubated for 4 h at 37 1C. At the end of the incubation, cells remaining on the top of the filter were removed by wiping. Filters were fixed in 3% formaldehyde in PBS and cells that had migrated to the underside of the transwells were with 1% crystal violet and counted under microscopy.
